One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration
Faricimab improved anatomical outcomes and allowed longer treatment intervals in patients with nAMD previously treated with other anti-VEGF therapies with unsatisfactory response, reducing treatment burden. A favorable safety profile was observed.
Authors
- A. Paris (ORCID: https://orcid.org/0000-0002-2908-3802)
- Moreno Menghini (ORCID: https://orcid.org/0000-0002-1432-2524)
- Giulio Volpe (ORCID: https://orcid.org/0000-0002-3891-2297)
- Michele Clerici
- Gabriela Grimaldi (ORCID: https://orcid.org/0000-0003-2435-7867)
- Angelica Rizzato
- Giuseppe Cancian (ORCID: https://orcid.org/0000-0002-9497-3166)
- Lia Agliati
Institutions
- Laboratory for Biomedical Neurosciences (CH)
- Ente Ospedaliero Cantonale (CH)
- Ospedale San Pietro Fatebenefratelli (IT)
Publication Details
- Journal
- Ophthalmology and Therapy
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1007/s40123-024-01036-4
- Citations
- 15
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 8.08